Hua Xia Shi Bao·2025-12-04 04:49Core Viewpoint - Rongchang Biopharmaceuticals is facing challenges due to restrictions on share reduction by major shareholders and ongoing financial losses despite revenue growth [1][6][7]. Shareholding and Management Changes - Since its listings in 2020 and 2022, Rongchang Biopharmaceuticals has experienced significant share reductions by financial investors, institutional shareholders, and some executives [2]. - Notably, former Chief Medical Officer He Ruyi reduced his holdings by nearly 650,000 shares, surpassing the reductions of two institutional shareholders combined [2][3]. - He Ruyi's departure, along with other key personnel, raises concerns about potential gaps in the company's R&D pipeline and strategic stability [4]. Financial Performance - In the first three quarters of the year, Rongchang Biopharmaceuticals reported total revenue of 1.72 billion yuan, a year-on-year increase of 42.27%, primarily driven by sales of its core drugs [6]. - However, the company continues to incur losses, with a net loss of 1.01 billion yuan in the third quarter and a cumulative net loss of 5.51 billion yuan for the year, leading to an accumulated undistributed profit of -4.873 billion yuan [7]. - The company's R&D investment decreased by 22.79% year-on-year to 891 million yuan, while sales expenses increased by 32.1% to 823 million yuan, indicating a high expenditure relative to revenue [8]. Industry Comparison - Rongchang Biopharmaceuticals has accumulated a net loss of nearly 4 billion yuan from 2022 to 2024, contrasting sharply with peers like Innovent Biologics, which have achieved profitability during the same period [7]. - The company’s financial scoring of 32 out of 100 places it at 307th among 391 companies in the biopharmaceutical sector, highlighting weaknesses in profitability and operational capabilities [9].